HomeAI · summaries
Storia in 6 fonti
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
Metsera has no products on the market, but it is developing oral and injectable treatments.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs
The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.
- ·
cnbc.com
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high U.S. drug costs.
- ·
fortune.com
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune
America's waistline may shrink, but its national debt will swell.
- ·
aljazeera.com
Weight-loss drug makers announce pricing agreement with Trump
The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
- ·
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
- ·
ilsole24ore.com
Pfizer vince la guerra con Novo Nordisk e acquisisce Metsera, startup di farmaci dimagranti
Pfizer pagherà fino a 86,25 dollari ad azione, di cui 65,60 dollari ad azione in contanti, più potenziali pagamenti aggiuntivi fino a 20,65 dollari ad azione
- ·
faz.net
Pfizer übertrumpft Novo in Bieterschlacht um Metsera
Zwei Pharmagiganten wollten ihre Stellung im umkämpften Markt für Adipositas-Medikamente stärken. Für den Sieg Pfizers könnten auch kartellrechtliche Bedenken eine Rolle gespielt…
- ·
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
Metsera has no products on the market, but it is developing oral and injectable treatments.
- ·
Novo Nordisk sale a Copenaghen, si ritira da gara miliardaria per Metsera
Accettata l'offerta rivista e migliorata di Pfizer da 10 miliardi di dollari che entra nel mercato dei farmaci contro l'obesità